RT Journal Article
SR Electronic
T1 Whole Exome and Transcriptome Sequencing of Stage-Matched, Outcome-Differentiated Cutaneous Squamous Cell Carcinoma Identifies Gene Expression Patterns Associated with Metastasis and Poor Outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.05.24302298
DO 10.1101/2024.02.05.24302298
A1 Nassir, Shams
A1 Yousif, Miranda
A1 Li, Xing
A1 Severson, Kevin
A1 Hughes, Alysia
A1 Kechter, Jacob
A1 Hwang, Angelina
A1 Boudreaux, Blake
A1 Bhullar, Puneet
A1 Zhang, Nan
A1 Butterfield, Duke
A1 Ma, Tao
A1 Ogbaudu, Ewoma
A1 Costello, Collin M
A1 Nelson, Steven
A1 DiCaudo, David J
A1 Sekulic, Aleksandar
A1 Baum, Christian
A1 Pittelkow, Mark
A1 Mangold, Aaron R
YR 2024
UL http://medrxiv.org/content/early/2024/02/06/2024.02.05.24302298.abstract
AB Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in humans and kills as many people annually as melanoma. The mutational and transcriptional landscape of cSCC has identified driver mutations associated with disease progression as well as key pathway activation in the progression of pre-cancerous lesions. The understanding of the transcriptional changes with respect to high-risk clinical/histopathological features and outcome is poor. Here, we examine stage-matched, outcome-differentiated cSCC and associated clinicopathologic risk factors using whole exome and transcriptome sequencing on matched samples. Exome analysis identified key driver mutations including TP53, CDKN2A, NOTCH1, SHC4, MIIP, CNOT1, C17orf66, LPHN22, and TTC16 and pathway enrichment of driver mutations in replicative senescence, cellular response to UV, cell-cell adhesion, and cell cycle. Transcriptomic analysis identified pathway enrichment of immune signaling/inflammation, cell-cycle pathways, extracellular matrix function, and chromatin function. Our integrative analysis identified 183 critical genes in carcinogenesis and were used to develop a gene expression panel (GEP) model for cSCC. Three outcome-related gene clusters included those involved in keratinization, cell division, and metabolism. We found 16 genes were predictive of metastasis (Risk score ≥ 9 Met & Risk score < 9 NoMet). The Risk score has an AUC of 97.1% (95% CI: 93.5% - 100%), sensitivity 95.5%, specificity 85.7%, and overall accuracy of 90%. Eleven genes were chosen to generate the risk score for Overall Survival (OS). The Harrell’s C-statistic to predict OS is 80.8%. With each risk score increase, the risk of death increases by 2.47 (HR: 2.47, 95% CI: 1.64-3.74; p<0.001) after adjusting for age, immunosuppressant use, and metastasis status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by: Dermatology Foundation Medical Dermatology Career Development Award, Mayo Clinic Investment for Extramural Grants Awards Program, Mayo Clinic Comprehensive Cancer Center Arnold and Kit Palmer Career Development Award in Cancer Research, and Mayo Clinic Cancer Center Desert Mountain Cares Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mayo Clinic Institutional Review Board IRB 21-012833 gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.